In the Title:

Please delete the title and insert therefor -- METHODS OF TREATING TNFα-MEDIATED CROHN'S DISEASE USING CHIMERIC ANTI-TNF ANTIBODIES --.

In the Abstract:

On page 165, line 4 after "*in vivo*", insert --for--;
line 5, after "pathologies and conditions," and insert therefor -- , including Crohn's disease,--;
line 10 delete "a genomic DNA sequence or a cDNA sequence."--.

In the Specification:

On page 1, line 6, after "1993" insert --,now abandoned,--;
line 8, after "1992" insert --,now abandoned,--;
line 12, after "07/607827," insert -- filed March 18, 1991--.

On page 12, delete lines 17 through 20 and insert therefor -- Figure 16 is a representation of a space filling model of a human TNF monomer and a representation of a space filling model of two non-contiguous peptide sequences of human TNF recognized by cA2. --.

On page 15, line 18, delete "light" and insert therefor -- heavy --;
line 22, delete "light" and insert therefor -- heavy --;
line 37, delete "The arrow marks the".

On page 16, line 1, delete "position of the truncated light chain".

On page 27, delete lines 4 through 7.

On page 38, line 12, delete "?? or".

On page 57, Line 1, delete "??" and insert therefor
-- selected--.

On page 98, line 29, delete "XIV" and insert therefor
-- XIII--.

On page 99, line 10, delete "XIV and XV" and insert therefor
-- XIII and XIV --;
line 27, delete "XIV and XV" and insert therefor
-- XIII and XIV --;
line 33, delete "XIV and XV" and insert therefor
-- XIII and XIV --.

On page 107, line 7, delete "flow chart" and insert
therefor --flow charts--;
line 8, delete "Table 9" and insert therefor
-- Table 9A and Table 9B --.

On page 140, line 11, delete "28A" and insert therefor
-- 28 --;
line 24, delete "pHC707 at a unique Xbal site
upstream;
line 25, delete "of the IgG1 coding sequences
(Figure 29)";
line 37, delete "28B" and insert therefore
-- 29 --.

In the Claims:

Please amend Claims 91, 94, 95, 96, and 97 as follows:

91. (Amended) A method of treating TNFα-mediated Crohn's disease in a human comprising administering to the human an effective TNF-inhibiting amount of an anti-TNF chimeric